Clinical Trial Detail

NCT ID NCT02650401
Title Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Ignyta, Inc.
Indications

neuroblastoma

central nervous system cancer

Advanced Solid Tumor

Therapies

Entrectinib

Age Groups: adult child

Additional content available in CKB BOOST